1.. INTRODUCTION
================

With more than 54,000 new cases and an estimated 13,000 deaths in the United States in 2008, renal cell carcinoma ([rcc]{.smallcaps}) shows a mortality rate that has declined slightly since 1990, but that continues to inflict a large burden of disease [@b1-co16-s1-s60]. Nephrectomy provides curative treatment for localized disease, but unfortunately, 30% of patients subsequently experience recurrence and metastasis, with survival rates below 10% [@b2-co16-s1-s60]. With accurate preoperative risk stratification, patients at high risk can be identified and offered neoadjuvant or adjuvant therapy for optimal management. The advent of small-molecule targeting agents such as sunitinib, sorafenib, and temsirolimus provides an avenue for such therapy in this patient population. We address such treatments here, and also discuss a pilot study currently under way at our centre to investigate neoadjuvant temsirolimus for high-risk [rcc]{.smallcaps}.

2.. APPROACH TO NEOADJUVANT OR ADJUVANT THERAPY
===============================================

2.1. Defining Risk
------------------

Although a complete discussion of the current status of risk stratification and prognostication in [rcc]{.smallcaps} is beyond the scope of this review, an accurate definition of risk in patients with [rcc]{.smallcaps} is imperative in determining those most likely to benefit from adjuvant and neoadjuvant therapy and in reducing toxicity in low-risk patients. We recommend a recent review by Downs *et al.* [@b3-co16-s1-s60] for a more comprehensive discussion of this important and rapidly evolving topic of risk assessment in [rcc]{.smallcaps}.

Currently, tumour stage continues to be the most important prognostic factor for patients with [rcc]{.smallcaps}. This understanding has been validated in a study of 2746 patients followed for a median of 9 years: 5-year cancer-specific survival rates by stage were 97% (pT1a), 87% (pT1b), 71% (pT2), 53% (pT3a), 44% (pT3b), 37% (pT3c), and 20% (pT4), using the 2002 American Joint Committee on Cancer tumour classification system [@b4-co16-s1-s60]. Within the current pT3 classification, the level of inferior vena cava involvement or the type of tissue invaded has failed to be associated with a significant difference in survival, and Terrone *et al.* further classified pT3 tumours by defining those invading either the perirenal or sinus fat to significantly constitute the lowest mortality risk [@b5-co16-s1-s60].

In addition to tumour stage, other parameters such as age, performance status, constitutional symptoms, number of metastatic sites, site of metastasis, sarcomatoid histology, papillary [rcc]{.smallcaps} type 2 histology, Fuhrman grade, microvascular tumour invasion, neutrophil count, serum lactate dehydrogenase level, serum C-reactive protein level, thyroid-stimulating hormone level, plasma adiponectin, oncofetal protein Imp3 (insulin-like growth factor [ii]{.smallcaps} m[rna]{.smallcaps}-binding protein 3), vascular endothelial growth factor ([vegf]{.smallcaps}), carbonic anhydrase [ix]{.smallcaps}, intratumoral polyamines, erythropoietin, B7-H1, and Ki-67 have illustrated prognostic and stratification utility in various studies [@b2-co16-s1-s60],[@b6-co16-s1-s60]--[@b17-co16-s1-s60]. Further studies are required with larger patient numbers and longer duration of follow-up to delineate the role of these variables in the natural history of [rcc]{.smallcaps}, to identify limitations, and to establish external validation of findings.

Recently devised integrated stratification systems attribute a value to various clinical and histologic features, and these combinations permit risk assessment within a defined patient population. The two most extensively studied integrated stratification systems for [rcc]{.smallcaps} are the Mayo Clinic stage, size, grade and necrosis ([ssign]{.smallcaps}) score for clear-cell [rcc]{.smallcaps} (cc[rcc]{.smallcaps}) and the University of California--Los Angeles ([ucla]{.smallcaps}) integrated staging system ([uiss]{.smallcaps}) for [rcc]{.smallcaps} [@b18-co16-s1-s60],[@b19-co16-s1-s60]. The [ssign]{.smallcaps} scoring algorithm was devised following an analysis of 1801 patients with unilateral cc[rcc]{.smallcaps}. The analysis revealed that the 1997 TNM staging system, tumour size greater than 5 cm, nuclear grade, and histologic necrosis are predictive of cancer-specific mortality [@b18-co16-s1-s60]. Patients with [ssign]{.smallcaps} scores of 0--2, 3--4, 5--6, and 7--9 have 5-year cancer-specific survival rates of 100%, 91%, 64%, and 47% respectively; all patients scoring 10 or more die of their disease within 2 years [@b3-co16-s1-s60].

The [uiss]{.smallcaps} system uses a combination of 1997 TNM stage, Fuhrman grade, and Eastern Cooperative Oncology Group performance status ([ecog]{.smallcaps}-[ps]{.smallcaps}) that was identified by Zisman *et al.,* through an analysis of 661 patients at [ucla]{.smallcaps}, as significantly predictive of cancer-specific survival [@b19-co16-s1-s60]. Initially, this method identified 5 statistically significant categories that stratified metastatic and nonmetastatic patients together, with 5-year survival in [uiss]{.smallcaps} categories [i]{.smallcaps}, [ii]{.smallcaps}, [iii]{.smallcaps}, [iv]{.smallcaps}, and [v]{.smallcaps} being 94%, 67%, 39%, 23%, and 0% respectively [@b19-co16-s1-s60]. These 5 categories were later incorporated into either metastatic or nonmetastatic low-risk, intermediate-risk, and high-risk stratifications, providing a practical means of assessing risk in patients with [rcc]{.smallcaps} not unlike the system used in prostate cancer [@b20-co16-s1-s60]. Reported 5-year disease-specific survival for low-, intermediate-, and high-risk nonmetastatic patients are 91%, 80%, and 54%; for metastatic patients, the corresponding rates are 32%, 20%, and 0%. To assign risk categories, decision boxes have been created for metastatic and nonmetastatic patients, in which risk is defined by progression downward from stage to grade to [ecog]{.smallcaps}-[ps]{.smallcaps}. In addition, analysis of freedom from recurrence in nonmetastatic patients revealed that 91% of low-risk, 64% of intermediate-risk, and 37% of high-risk patients are free from any recurrence at 5 years. Given these statistically significant differences in recurrence, and a tendency for low-risk patients to recur in the chest (high-risk patients recur in the abdomen), various postoperative surveillance regimens have been defined [@b21-co16-s1-s60],[@b22-co16-s1-s60].

Both of these integrative models have been externally validated: the [uiss]{.smallcaps} with at least 8249 patients, and the [ssign]{.smallcaps} with 2656 patients [@b23-co16-s1-s60]--[@b26-co16-s1-s60]. Regarding predictive capacity, the [ssign]{.smallcaps} score appears to be slightly superior to the [uiss]{.smallcaps} in nonmetastatic patients, having shown a predictive accuracy of 0.830 as compared with 0.760 in one study of 388 patients. However, the authors of the latter study did not report whether the difference was statistically significant, and clinical significance has yet to be established [@b27-co16-s1-s60]. Nevertheless, recent findings indicate that the addition of 5 molecular markers to the [uiss]{.smallcaps} increases its predictive accuracy to 0.903 [@b27-co16-s1-s60]. The [uiss]{.smallcaps} system is currently limited by the complexity and technical demands of obtaining molecular markers from all patients. A potential limitation of the [ssign]{.smallcaps} system is its reliance on histologic tumour necrosis, which does not have a standardized definition, consensus for reporting, or availability at many centres [@b27-co16-s1-s60]. Lastly, it should be noted that the [ssign]{.smallcaps} is applicable only to patients with cc[rcc]{.smallcaps} ([Table [i]{.smallcaps}](#t1-co16-s1-s60){ref-type="table"}).

Nomograms have also been developed to elucidate the prognosis of patients with [rcc]{.smallcaps}; however, although these tools are useful for individuals, they do not stratify patients into risk groups, thus limiting their role in clinical trial design and implementation of adjuvant and neoadjuvant therapy [@b28-co16-s1-s60]--[@b31-co16-s1-s60].

2.2. Adjuvant Therapy
---------------------

Much effort has been invested toward the development of an effective and pragmatic strategy for adjuvant treatment of [rcc]{.smallcaps}. The use of radiation therapy was investigated in this light and found to be equivalent to observation in terms of relapse rate and survival [@b32-co16-s1-s60],[@b33-co16-s1-s60]. Furthermore, this modality expressed significant morbidity and mortality with a 44% complication rate [@b32-co16-s1-s60]. Currently, radiation therapy in the adjuvant setting has been abandoned and is being used only for palliation of symptomatic bone metastases.

The use of hormonal therapy has also been explored as a potential for adjuvant treatment of high-risk [rcc]{.smallcaps}. In a prospective randomized study of 136 patients, medroxyprogesterone acetate was found to provide no benefit with regard to disease recurrence and was associated with significant toxicity [@b34-co16-s1-s60].

Immunotherapy has been another area of active investigation as an adjuvant strategy in [rcc]{.smallcaps}. A modest benefit in survival was reported with interferon alfa ([ifn]{.smallcaps}α) and with interleukin-2 ([il]{.smallcaps}-2) therapy in the context of metastatic [rcc]{.smallcaps}, but these immune modulators do not currently have a defined role in the adjuvant setting. In randomized trials, adjuvant [ifn]{.smallcaps}α and the widely available recombinant [ifn]{.smallcaps}α2b have been shown not to contribute to survival or relapse-free survival [@b35-co16-s1-s60],[@b36-co16-s1-s60]. For example, a phase [iii]{.smallcaps} trial investigating adjuvant [il]{.smallcaps}-2 in high-dose bolus form was closed early because an interim analysis revealed that disease-free survival was not affected [@b37-co16-s1-s60]. A subsequent study investigating adjuvant [il]{.smallcaps}-2 in low-dose subcutaneous form was also ineffective with respect to disease-free survival [@b38-co16-s1-s60].

A more passive method of immunomodulation and its application to adjuvant therapy in [rcc]{.smallcaps} has come in the form of tumour vaccines. Galligioni *et al.* investigated the use of autologous irradiated tumour cells mixed with bacillus Calmette--Guèrin as an adjuvant strategy and found no statistically significant improvement in overall or disease-free survival [@b39-co16-s1-s60], but a multicentre phase [iii]{.smallcaps} randomized controlled trial of adjuvant autologous tumour-cell vaccine conducted in Germany show a statistically significant disease-free survival benefit [@b40-co16-s1-s60]. In the latter investigation, 379 patients with pT2--3b pN0--3 M0 disease were included in the analysis, and 5-year progression-free survival was 77.4% and 67.8% in the vaccine and the control groups respectively. That study has been widely criticized because 174 patients were lost to follow-up after randomization and also because differences in overall survival were not analyzed.

Another vaccine strategy has focused on the use of heat shock proteins. The heat shock protein peptide complex HSPPC-96 (vitespen) was developed from autologous tumours in [rcc]{.smallcaps}. Following encouraging results in a phase [ii]{.smallcaps} trial, a 728-patient multicentre open-label randomized phase [iii]{.smallcaps} trial compared adjuvant HSPPC-96 with observation following nephrectomy and found no difference in recurrence-free survival after a median follow-up of 1.9 years [@b41-co16-s1-s60].

The use of monoclonal antibodies has also been considered in the adjuvant treatment of [rcc]{.smallcaps}. Recently, an immunoglobulin G1 antibody known as cG250 (WX-G250) was found to bind carbonic anhydrase [ix]{.smallcaps}, which is a [rcc]{.smallcaps}-specific tumour antigen. A phase [iii]{.smallcaps} trial investigating the use of cG250 as compared with placebo following nephrectomy \[the [ariser]{.smallcaps} (Adjuvant Rencarex Immunotherapy Trial to Study Efficacy in Nonmetastasized RCC) study\] is currently in progress, with results expected in 2013 [@b42-co16-s1-s60].

A new frontier in the adjuvant treatment of [rcc]{.smallcaps} has focused on the use of small-molecule kinase inhibitors and anti-vascular agents. Although no substantial studies have yet justified the use of these agents in the adjuvant setting, sorafenib [@b43-co16-s1-s60], sunitinib [@b44-co16-s1-s60], and temsirolimus [@b45-co16-s1-s60] have been established as appropriate treatment options in metastatic [rcc]{.smallcaps}. These agents are thought to work through a mechanism influencing the involvement of the tumor-suppressor *VHL* gene in the pathogenesis of [rcc]{.smallcaps}. Spontaneous inactivation of *VHL* in sporadic cases of [rcc]{.smallcaps} results in the overexpression of [vegf]{.smallcaps}s, platelet-derived growth factors ([pdgf]{.smallcaps}s) and hypoxia-inducible factors ([hif]{.smallcaps}s) [@b44-co16-s1-s60]. Sorafenib and sunitinib reduce tumour-cell proliferation and angiogenesis by acting as small-molecule inhibitors of multiple kinases; [vegf]{.smallcaps} receptors 1, 2, and 3; [pdgf]{.smallcaps} beta receptors; and [fms]{.smallcaps}-like tyrosine kinase 3 (Flt3), among others [@b46-co16-s1-s60]. Temsirolimus is a mammalian target of rapamycin kinase inhibitor and antagonizes cell growth and proliferation by disrupting intracellular signalling pathways. Furthermore, temsirolimus blocks [hifa]{.smallcaps}, which drives the downstream regulation of a number of pro-angiogenic factors [@b45-co16-s1-s60].

Given the favourable effect of these agents in the treatment of metastatic [rcc]{.smallcaps}, several trials are now underway to evaluate their use as adjuvant therapies in high-risk surgically resectable [rcc]{.smallcaps} ([Table [ii]{.smallcaps}](#t2-co16-s1-s60){ref-type="table"}). The [assure]{.smallcaps} trial is a multicentre double-blind randomized study examining 1332 patients who underwent nephrectomy for pT1b, G3--4; pT2--pT4; or any T stage with node-positive disease. Patients will be stratified into intermediate high-risk or very high-risk groups and then randomized for 1 year of oral sorafenib, sunitinib, or placebo. Very high-risk patients are those with grades 3--4 pT3a, any pT3a with adrenal involvement, or pT3b--4 and any N+. Intermediate high-risk patients are those with grades 3--4 pT1b, any pT2, or grades 1--2 pT3a without adrenal involvement. In addition to disease-free and overall survival, the study will investigate biomarkers, genetic mutations, [dna]{.smallcaps} methylation, and genetic polymorphisms as predictors of survival and therapeutic benefit. The investigation commenced in May 2006, and the estimated date of completion is April 2016. (For details, search for "NCT00326898" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search))

Another ongoing adjuvant trial called the [sorce]{.smallcaps} trial is a multicentre double-blind randomized study with an estimated enrolment of 1656 patients with resected primary [rcc]{.smallcaps} at high- or intermediate-risk of relapse (defined by investigators as a Leibovich score of 3--11). Patients are to be randomized to receive either sorafenib for 1 year, sorafenib for 3 years, or placebo. The primary outcome measure is disease-free survival; secondary outcome measures are metastasis-free survival, overall survival, cost effectiveness, and toxicity. The [sorce]{.smallcaps} trial opened recruitment in June 2007 and is estimated to be completed by August 2012. (For details, search for "NCT00492258" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search))

A third trial known as [s]{.smallcaps}-[trac]{.smallcaps} addresses the use of adjuvant sunitinib. With a multicentre double-blind randomized design, this study will compare 1 year of oral sunitinib with placebo in 290 patients at high risk of recurrence (based on [uiss]{.smallcaps} criteria) following nephrectomy. The primary endpoint of the study is disease-free survival, and secondary endpoints to be assessed will be overall survival, safety, and patient-recorded outcomes. The projected timeline for this investigation is July 2007 to March 2011 [@b47-co16-s1-s60]. (For details, search for "NCT00375674" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search))

2.3. Neoadjuvant Therapy
------------------------

A review of the current literature failed to reveal any prospective studies in the field of neoadjuvant therapy for high-risk [rcc]{.smallcaps}. Until recently, cytokine-based immunotherapy had been the mainstay of systemic therapy in [rcc]{.smallcaps}, but its significant toxicity and poor primary tumour response are believed to have limited any investigations in the neoadjuvant setting [@b47-co16-s1-s60]. However, with the advent and subsequent success of small-molecule inhibitors for advanced [rcc]{.smallcaps} [@b39-co16-s1-s60]--[@b41-co16-s1-s60], the prospect of their application in a neoadjuvant strategy is provocative and exciting. Certainly, the theoretical benefits are intriguing and include tumour downstaging, reduction in pro-angiogenic factors, and possible response in the primary tumour. Several centres have published stimulating case reports demonstrating that neoadjuvant treatment with various permutations of sorafenib, sunitinib, and bevacizumab resulted in a reduction of primary tumour size [@b47-co16-s1-s60]--[@b49-co16-s1-s60], tumour thrombus [@b47-co16-s1-s60],[@b49-co16-s1-s60], bulky lymphadenopathy [@b47-co16-s1-s60],[@b48-co16-s1-s60], and metastatic lesions [@b47-co16-s1-s60].

3.. McMASTER UNIVERSITY EXPERIENCE
==================================

Currently, there is a paucity of knowledge on the biologic response of [rcc]{.smallcaps} to small-molecule inhibitors *in vivo.* This, along with the exciting potential of the application of these agents in the neoadjuvant setting of high-risk [rcc]{.smallcaps} patients, has compelled our centre to undertake a nonrandomized open-label outpatient pilot study investigating the use of temsirolimus before nephrectomy in patients with high-risk and metastatic [rcc]{.smallcaps}. Patients receive 25 mg temsirolimus by intravenous infusion on a weekly basis for 12 weeks before nephrectomy. Patients with metastatic disease continue to receive the same dose postoperatively for a maximum of 24 months, or until disease progression. A renal-mass biopsy and biomarker analysis is performed upon entry into the study. Efficacy will be evaluated using the Response Evaluation Criteria in Solid Tumors, and safety will be evaluated using the National Cancer Institute Common Toxicity Criteria for Adverse Events. The approximate duration of this study is 5 years, with an estimated enrolment of 20 subjects.

To date, 5 patients have been enrolled in the trial. Three patients have undergone uneventful laparoscopic radical nephrectomy. Patient 1 (10-cm renal mass with bulky adenopathy T2N2M0) is [ned]{.smallcaps} (no evidence of disease) at 6 months post-nephrectomy. Patient 2 (9-cm renal mass, bulky adenopathy, pulmonary metastases T2N2M1) is [ned]{.smallcaps} at 3 months post-nephrectomy. Patient 3 (7-cm renal mass, pulmonary metastases, T2N0M1) has recently undergone uneventful surgery, and follow-up computed tomography is pending. Patients 4 and 5 are receiving weekly temsirolimus, and surgery is planned.

These preliminary and early results suggest that neoadjuvant temsirolimus before radical nephrectomy for advanced [rcc]{.smallcaps} may induce disease regression post-surgery, and may even lead to disease resolution in patients with low-volume disease. Longer term follow-up is necessary to assess overall progression-free survival and overall survival.

4.. CONCLUSIONS
===============

In summary, the role, efficacy, and toxicity of adjuvant and neoadjuvant targeted small-molecule inhibitors in high-risk [rcc]{.smallcaps} remain to be delineated. Ideally, clinicians will be able to identify high-risk patients and to offer treatment to those who would benefit most from adjuvant and neoadjuvant therapy, while minimizing toxicity in low-risk patients.

###### 

Comparison of the clinical stage, size, grade, and necrosis ([ssign]{.smallcaps}) score and the University of California--Los Angeles integrated staging system ([uiss]{.smallcaps}) integrated models of risk stratification

  *Model*               *Parameters*                                                    *Histology validation*   *External (*n*)*   *Patients*   *Limitations*
  --------------------- --------------------------------------------------------------- ------------------------ ------------------ ------------ ----------------------------------------------------
  [ssign]{.smallcaps}   TNM stage, size, grade, necrosis                                cc[rcc]{.smallcaps}      Yes                2656         Reliance upon subjective variable of necrosis
  [uiss]{.smallcaps}    [ecog]{.smallcaps}-[ps]{.smallcaps}, Fuhrman grade, TNM stage   [rcc]{.smallcaps}        Yes                8249         Reduced predictive power in nonmetastatic patients

TMN = tumour size, metastasis, and nodal involvement staging system; cc[rcc]{.smallcaps} = clear-cell renal cell carcinoma; [ecog]{.smallcaps}-[ps]{.smallcaps} = Eastern Cooperative Oncology Group performance status; [rcc]{.smallcaps} = renal cell carcinoma.

###### 

Ongoing adjuvant therapy trials for high-risk renal cell carcinoma ([rcc]{.smallcaps})

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Trial name*                                                                                                                                                                            *Principal investigator*                                       *Estimated accrual (*n*)*   *Treatment arms*                                                                               *Primary outcome*       *Estimated date of completion*
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------- ----------------------- --------------------------------
  [assure]{.smallcaps}\                                                                                                                                                                   N.S. Blazer--Haas, *et al.* National Cancer Institute          1332                        Sunitinib: orally every other day; 4 weeks on, 2 weeks rest, and 6 weeks placebo sorafenib;\   Disease-free survival   Apr 2016
   (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma)                                                                                                                                                                                                                 vs. sorafenib: orally twice daily; 6 weeks on, 4 weeks placebo sunitinib, and 2 weeks rest;\                           
                                                                                                                                                                                                                                                                                     vs. placebo                                                                                                            

  [sorce]{.smallcaps}\                                                                                                                                                                    T. Eisen, Cancer Research UK at Cambridge Research Institute   1656                        Sorafenib: orally twice daily; 1 year on and 2 years' placebo;\                                Disease-free survival   Aug 2012
   (Phase [iii]{.smallcaps} Randomized Double-blind Study Comparing Sorafenib with Placebo in Patients with Resected Primary [rcc]{.smallcaps} at High or Intermediate Risk of Relapse)                                                                                              vs. sorafenib: orally twice daily; 3 years on;\                                                                        
                                                                                                                                                                                                                                                                                     vs. placebo                                                                                                            

  [s]{.smallcaps}-[trac]{.smallcaps}\                                                                                                                                                     Pfizer Inc.                                                    290                         Sunitinib: orally every other day; 4 weeks on, 2 weeks rest, and 6 weeks placebo sorafenib;\   Disease-free survival   Sep 2011
   (Sunitinib Treatment of Renal Adjuvant Cancer)                                                                                                                                                                                                                                    vs. sorafenib: orally twice daily; 6 weeks on, 4 weeks placebo sunitinib, and 2 weeks rest)\                           
                                                                                                                                                                                                                                                                                     vs. placebo                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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